45 reports

  • 6.1 INTRODUCTION
  • FUNCTIONAL FOOD INGREDIENTS MARKET SIZE, BY TYPE, 2016-2023 (USD MILLION)

PREBIOTICS RESIST GASTRIC ACIDITY AND HYDROLYSIS CAUSED BY ENZYMES AND GASTROINTESTINAL ABSORPTION.

  • Lipid Modifying Drug
  • Mineral Supplement
  • Market Size
  • Arla Foods
  • Cargill Inc.

One of the major reasons for the high bioavailability of organic minerals is that, unlike inorganic minerals, these do not interact with fiber, tannin, phytate, silicates, oxalate, or other minerals in the gastrointestinal tract.

  • Mineral Supplement
  • Pig
  • World
  • Alltech Inc.
  • Kemin Industries, Inc.

THE MICROPEARLS SPRAY FREEZING TECHNOLOGY ALLOWS FOR THE TIMELY RELEASE OF THESE ## KEY NUTRIENTS THROUGHOUT AN ANIMAL' S GASTROINTESTINAL TRACT.

  • Mineral Supplement
  • North America
  • United States
  • World
  • Market Size
  • VITAMIN & MINERAL PREMIXES MARKET, BY FUNCTIONALITY

Q. ##.

  • Lipid Modifying Drug
  • Mineral Supplement
  • Market Size
  • Glanbia plc
  • Nutreco N.V.

MARKET ##.

  • Mineral Supplement
  • APAC
  • Japan
  • World
  • Demand
  • 7.1 Nutrition/Therapeutic

TABLE OF CONTENTS ##.

  • Lipid Modifying Drug
  • Mineral Supplement
  • Archer Daniels Midland Company
  • Boehringer Ingelheim GmbH
  • Darling Ingredients Inc.

You can easily book an appointment with one online.

  • Mineral Supplement
  • World
  • Market Size
  • Alltech Inc.
  • Kemin Industries, Inc.
  • BILE ACID SEQUESTRANTS
  • LOSS OF PATENT EXCLUSIVITY OF BRANDED THERAPIES

The prevalence rate for FH ranges between one in ## to one in ## people.

  • Lipid Modifying Drug
  • Mineral Supplement
  • AstraZeneca PLC
  • Merck & Co., Inc.
  • Pfizer Inc.
  • 13.3 Factors that impede market growth

Bile acid sequestrates lead to side effects related to the gastrointestinal tract.

  • Cholesterol
  • Lipid Modifying Drug
  • Mineral Supplement
  • World
  • AstraZeneca PLC
  • WELCHOL SWOT ANALYSIS, 2015
  • 6.12 BILE ACID SEQUESTRANTS

PLOS ONE; ##(##): ##-##.

  • Lipid Modifying Drug
  • AstraZeneca PLC
  • Cerenis
  • Merck & Co., Inc.
  • The Medicines Company

It is used to enhance rumen and gastrointestinal tract function.

  • Lipid Modifying Drug
  • Mineral Supplement
  • World
  • Market Size
  • Nutreco N.V.

Dietary fibers can act by changing the nature of the contents of the gastrointestinal tract and by changing how other nutrients and chemicals are absorbed.

  • Mineral Supplement
  • China
  • Demand
  • Amway Corporation
  • Joincare Pharmaceutical Group Industry Co., Ltd.

Dietary fibers can act by changing the nature of the contents of the gastrointestinal tract and by changing how other nutrients and chemicals are absorbed.

  • Energy
  • Mineral Supplement
  • Vitamin
  • China
  • Demand

MARKET SEGMENTATION ##.

  • Mineral Supplement
  • Argentina
  • Croda International Plc
  • Danone SA
  • General Mills, Inc.

The alleviation of gastrointestinal morbidity and other diseases in livestock, such as swine dysentery and acidosis in ruminants, is another advantage of feed ingredients enzymes.

  • Mineral Supplement
  • Colombia
  • South America
  • Market Size
  • Alltech Inc.

It is estimated that worldwide one in five men and one in three women are at risk of an osteoporotic fracture.

  • Mineral Supplement
  • World
  • Forecast
  • Quidel Corporation
  • Roche Group

The subsidiary is focused on aging care, critical care & surgery, gastrointestinal function, and pediatrics.

  • Lipid Modifying Drug
  • Mineral Supplement
  • North America
  • United States
  • Demand

Q. ##.

  • Lipid Modifying Drug
  • Meat
  • Mineral Supplement
  • Cargill Inc.
  • Koninklijke DSM N.V.
  • PRODUCT PROFILE - EPANOVA (OMEGA-3 CARBOXYLIC ACIDS)
  • WELCHOL (COLESEVELAM HCL) SWOT ANALYSIS, 2014

GASTROINTESTINAL SIDE EFFECTS WERE THE MOST COMMON AND INCLUDED ERUCTATION, DIARRHEA, AND NAUSEA.

  • Lipid Modifying Drug
  • World
  • AstraZeneca PLC
  • Merck & Co., Inc.
  • Pfizer Inc.

Drivers and their Impact Impact on Key Customer Category Increase in Incidence of High Cholesterol Increase in Prevalence of Chronic Diseases Changes in Cholesterol Treatment Guidelines Increase in Aging Population Expected Entry of Cost- Effective OTC Versions ## ## ## ## ## Hospitals Low Low

  • Lipid Modifying Drug
  • AstraZeneca PLC
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • PRODUCT PROFILE - EPANOVA (OMEGA-3 CARBOXYLIC ACIDS)
  • WELCHOL (COLESEVELAM HCL) SWOT ANALYSIS, 2014

GASTROINTESTINAL SIDE EFFECTS WERE THE MOST COMMON AND INCLUDED ERUCTATION, DIARRHEA, AND NAUSEA.

  • Lipid Modifying Drug
  • World
  • AstraZeneca PLC
  • Merck & Co., Inc.
  • Pfizer Inc.
  • PRODUCT PROFILE - EPANOVA (OMEGA-3 CARBOXYLIC ACIDS)
  • WELCHOL (COLESEVELAM HCL) SWOT ANALYSIS, 2014

GASTROINTESTINAL SIDE EFFECTS WERE THE MOST COMMON AND INCLUDED ERUCTATION, DIARRHEA, AND NAUSEA.

  • Lipid Modifying Drug
  • World
  • AstraZeneca PLC
  • Merck & Co., Inc.
  • Pfizer Inc.
  • PRODUCT PROFILE - EPANOVA (OMEGA-3 CARBOXYLIC ACIDS)
  • WELCHOL (COLESEVELAM HCL) SWOT ANALYSIS, 2014

GASTROINTESTINAL SIDE EFFECTS WERE THE MOST COMMON AND INCLUDED ERUCTATION, DIARRHEA, AND NAUSEA.

  • Lipid Modifying Drug
  • World
  • AstraZeneca PLC
  • Merck & Co., Inc.
  • Pfizer Inc.

S##. and Rehabilitation; ##(##): ##-##.

  • Lipid Modifying Drug
  • AstraZeneca PLC
  • GlaxoSmithKline plc
  • Merck & Co., Inc.
  • Pfizer Inc.
  • GLOBAL MARKETS DIRECT REPORT COVERAGE

It acts by targeting free fatty acid receptor ## (GPR##).

  • Diabetes
  • Lipid Modifying Drug
  • United States
  • Product Initiative
  • GlaxoSmithKline plc
  • SMALL MOLECULE TO ANTAGONIZE GABAA RECEPTOR FOR METABOLIC, GASTROINTESTINAL AND CARDIOVASCULAR DISORDERS - DRUG PROFILE
  • DYSLIPIDEMIA - PIPELINE BY JEIL PHARMACEUTICAL CO LTD, H1 2018

Dyslipidemia - Pipeline Review, H1 2018 Summary Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Dyslipidemia - Pipeline Review, H1 2018, provides an overview of the Dyslipidemia (Metabolic Disorders) pipeline landscape. Dyslipidemia is defined as elevation...

  • Cholesterol
  • Chronic Disease
  • Lipid Modifying Drug
  • Mineral Supplement
  • Amarin Corporation plc

It provides products across various therapeutic areas including hematology, neuroscience, immunology, genetic disease, ophthalmic, gastrointestinal, endocrine, hereditary angioedema, cancer and other diseases.

  • Endocrine Disease
  • Mineral Supplement
  • United States
  • World
  • Product Initiative
  • HYPERLIPIDEMIA - PIPELINE BY LOTUS PHARMACEUTICAL CO., LTD., H1 2016
  • HYPERLIPIDEMIA - PIPELINE BY ALLERGAN PLC, H1 2016

The company also focuses in the infection, neuroscience and gastrointestinal (ING) disease areas.

  • Endocrine Disease
  • Lipid Modifying Drug
  • Mineral Supplement
  • United States
  • Product Initiative
  • GLOBAL MARKETS DIRECT REPORT COVERAGE

Report covers products from therapy areas Metabolic Disorders, Undisclosed and Gastrointestinal which include indications Unspecified, Diabetes, Type ## Diabetes, Non Alcoholic Fatty Liver Disease (NAFLD) and Non- Alcoholic Steatohepatitis (NASH).

  • Lipid Modifying Drug
  • Molecular Diagnostic
  • United States
  • Product Initiative
  • GlaxoSmithKline plc
  • LOMITAPIDE: PHARMACOKINETIC PROPERTIES
  • LOMITAPIDE: PATENT PORTFOLIO

THE MOST COMMON ADVERSE REACTIONS ARE GASTROINTESTINAL, REPORTED BY ##% OF PATIENTS TESTED.

  • Lipid Modifying Drug
  • United States
  • Demand
  • Pfizer Inc.
  • Sanofi S.A.